The discovery of the DNA structure sparked a flurry of new research, birthing fields like molecular biology, biotechnology, ...
A major medical milestone took place in May 2025, when doctors at the Children’s Hospital of Philadelphia used CRISPR-based ...
CRISPR Therapeutics AG is rated a Buy with $1.9B cash, prudent management, and undervalued shares. Learn more about CRSP ...
Q3 2025 Management View President & COO Joseph Hazelton highlighted a pivotal shift, stating Dyadic is now operating as a “commercially focused biotechnology company with a growing portfolio of ...
From revolutionary CRISPR treatment to heavy drinking dangers, here's what you need to know about the latest health research.
Thinking about CRISPR Therapeutics and wondering if now is your chance to scoop up value, or if the stock is already priced in with the excitement? Let's break down what the numbers and news say about ...
An experimental gene-editing treatment shows promise for permanently lowering levels of cholesterol and triglycerides, ...
An experimental gene-editing therapy developed by Crispr Therapeutics is showing promise for treating heart disease.